JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C)

Leukemia Research

Volumn 33, Issue 11, 2009, Pages 1525-1529

  Shami, Paul J ^a   Maciag, Anna E ^b   Eddington, Jordan K ^a   Udupi, Vidya ^a   Kosak, Ken M ^a   Saavedra, Joseph E ^b   Keefer, Larry K ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Acute myeloid leukemia; Cytarabine; JS K; Nitric oxide; Synergy

Indexed keywords

(2,4 DINITROPHENYL) 1 [(4 ETHOXYCARBONYL)PIPERAZIN 1 YL]DIAZEN 1 IUM 1,2 DIOLATE; CYTARABINE; DAUNORUBICIN; DNA; ETOPOSIDE; NITRIC OXIDE DONOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HL 60; CHEMICAL INTERACTION; CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MYELOID LEUKEMIA; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL;

AZO COMPOUNDS; COMET ASSAY; CYTARABINE; DRUG SYNERGISM; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID; NITRIC OXIDE DONORS; PIPERAZINES;

EID: 68649112811     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.01.002     Document Type: Article

References (20)

1. Magrinat G., Mason S.N., Shami P.J., and Weinberg J.B. Nitric oxide modulation of human leukemia cell differentiation and gene expression. Blood 80 (1992) 1880-1884
2. Shami P.J., Moore J.O., Gockerman J.P., Hathorn J.W., Misukonis M.A., and Weinberg J.B. Nitric oxide modulation of the growth and differentiation of freshly isolated acute non-lymphocytic leukemia cells. Leukemia Res 19 (1995) 527-533
3. Shami P.J., Sauls D.L., and Weinberg J.B. Schedule and concentration-dependent induction of apoptosis in leukemia cells by nitric oxide. Leukemia 12 (1998) 1461-1466
4. Moncada S., Palmer R.M.J., and Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43 (1991) 109-142
5. Shami P.J., Saavedra J.E., Wang L.Y., Bonifant C.L., Diwan B.A., Singh S.V., Gu Y., Fox S.D., Buzard G.S., Citro M.L., Waterhouse D.J., Davies K.M., Ji X., and Keefer L.K. JS-K, a glutathione S-transferase-activated nitric oxide donor with potent anti-neoplastic activity. Mol Cancer Ther 2 (2003) 409-417
6. Baines P., Cumber P., and Padua R.A. Multidrug resistance in leukaemia. Baillieres Clin Hematol 5 (1992) 943-960
7. Sargent J.M., Williamson C., Hall A.G., Elgie A.W., and Taylor C.G. Evidence for the involvement of the glutathione pathway in drug resistance in AML. Adv Exp Med Biol 457 (1999) 205-209
8. 2-aryl diazeniumdiolates in vitro and in vivo. J Med Chem 49 14 (2006) 4356-4366
9. NAr reactions. J Org Chem 66 (2001) 3090-3098
10. Chou T.-C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22 (1984) 27-55
11. Singh N.P., McCoy M.T., Tice R.R., and Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175 (1988) 184-191
12. Kiziltepe T., Hideshima T., Ishitsuka K., Ocio E.M., Raje N., Catley L., Li C.-Q., Trudel L.J., Yasui H., Vallet S., Kutok J.L., Chauhan D., Mitsiades C.S., Saavedra J.E., Wogan G.N., Keefer L.K., Shami P.J., and Anderson K.C. JS-K, a GST-activated nitric oxide generator, induces DNA double strand breaks, activates DNA damage response pathways, and induces apoptosis in human multiple myeloma cells. Blood 110 (2007) 709-718
13. Townsend D.M., Findlay V.J., Fazilev F., Ogle M., Fraser J., Saavedra J.E., Ji X., Keefer L.K., and Tew K.D. A glutathione S-transferase π-activated prodrug causes kinase activation concurrent with S-glutathionylation of proteins. Mol Pharmacol 69 (2006) 501-508
14. Udupi V., Yu M., Malaviya S., Saavedra J.E., and Shami P.J. JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells. Leukemia Res 30 (2006) 1279-1283
15. Chu E., Mota A.C., and Fogarasi M.C. Antimetabolites. In: DeVita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer principles and practice of oncology. 6th ed. (2001), Lippincott Williams and Wilkins, New York, NY 388-415
16. Nguyen T., Brunson D., Crespi C.L., Penman B.W., Wishnok J.S., and Tannenbaum S.R. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci USA 89 (1992) 3030-3034
17. 6-methylguanine-DNA-methyltransferase. Carcinogenesis 15 (1994) 443-447
18. Sidorkina O., Espey M.G., Miranda K.M., Wink D.A., and Laval J. Inhibition of poly(ADP-ribose) polymerase (PARP) by nitric oxide and reactive nitrogen oxide species. Free Radic Biol Med 35 (2003) 1431-1438
19. Graziewicz M., Wink D.A., and Laval F. Nitric oxide inhibits DNA ligase activity: potential mechanisms of NO-mediated DNA damage. Carcinogenesis 17 (1996) 2501-2505
20. Wink D.A., and Laval J. The Fpg protein, a DNA repair enzyme, is inhibited by the biomediator nitric oxide in vitro and in vivo. Carcinogenesis 15 (1994) 2125-2129